FERRO, Stefania
 Distribuzione geografica
Continente #
NA - Nord America 10.383
EU - Europa 5.649
AS - Asia 3.325
SA - Sud America 1.379
AF - Africa 121
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 20.869
Nazione #
US - Stati Uniti d'America 10.239
RU - Federazione Russa 1.957
SG - Singapore 1.369
BR - Brasile 1.224
IE - Irlanda 1.011
CN - Cina 908
SE - Svezia 870
HK - Hong Kong 412
UA - Ucraina 391
IT - Italia 368
DE - Germania 325
VN - Vietnam 280
FI - Finlandia 214
GB - Regno Unito 195
IN - India 107
FR - Francia 94
AR - Argentina 64
CA - Canada 64
MX - Messico 54
CZ - Repubblica Ceca 43
BE - Belgio 38
PL - Polonia 35
ZA - Sudafrica 35
IQ - Iraq 31
BD - Bangladesh 28
JP - Giappone 28
TR - Turchia 26
MA - Marocco 25
EC - Ecuador 24
CI - Costa d'Avorio 23
ES - Italia 18
UZ - Uzbekistan 18
AT - Austria 17
CO - Colombia 17
NL - Olanda 17
ID - Indonesia 14
PY - Paraguay 11
EG - Egitto 10
KE - Kenya 10
PE - Perù 9
UY - Uruguay 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
KG - Kirghizistan 8
PK - Pakistan 8
DO - Repubblica Dominicana 7
NP - Nepal 7
OM - Oman 7
CH - Svizzera 6
CL - Cile 6
LV - Lettonia 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
BO - Bolivia 5
GR - Grecia 5
IR - Iran 5
KZ - Kazakistan 5
AL - Albania 4
CR - Costa Rica 4
IL - Israele 4
LK - Sri Lanka 4
MD - Moldavia 4
PA - Panama 4
RO - Romania 4
TN - Tunisia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BY - Bielorussia 3
GT - Guatemala 3
JM - Giamaica 3
KR - Corea 3
LB - Libano 3
LT - Lituania 3
LU - Lussemburgo 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CG - Congo 2
DZ - Algeria 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
MY - Malesia 2
NG - Nigeria 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
BN - Brunei Darussalam 1
BW - Botswana 1
CY - Cipro 1
Totale 20.855
Città #
Dallas 5.016
Dublin 1.009
Moscow 945
Jacksonville 779
Chandler 726
Singapore 629
Nyköping 577
Ashburn 566
Beijing 439
Hong Kong 411
Princeton 179
Dearborn 170
Cambridge 167
Los Angeles 162
Medford 160
Des Moines 132
Ann Arbor 127
The Dalles 124
Messina 123
Dong Ket 116
Boardman 106
São Paulo 86
Buffalo 72
Ho Chi Minh City 68
Lancaster 60
New York 59
Wilmington 48
Woodbridge 48
Hyderabad 41
Jinan 41
San Mateo 40
Pune 38
Redondo Beach 37
Brussels 36
Munich 35
Shenyang 34
Belo Horizonte 33
Tianjin 32
Brasília 30
Brno 30
Catania 29
Nanjing 28
Rio de Janeiro 28
Brooklyn 27
Denver 25
Tokyo 24
Abidjan 23
Johannesburg 23
Turku 23
Frankfurt am Main 22
Lappeenranta 22
Phoenix 22
Hanoi 21
Warsaw 21
Düsseldorf 20
Haikou 20
Hebei 20
Houston 20
Montreal 20
Atlanta 19
Seattle 19
London 18
Orem 18
Tashkent 18
Chicago 17
Santa Clara 17
Baghdad 16
Hangzhou 16
Porto Alegre 16
Goiânia 15
Ningbo 15
Guarulhos 14
Lauterbourg 14
Mexico City 14
Stockholm 14
Taizhou 14
Vienna 14
Guangzhou 13
Milan 13
Ottawa 13
Campinas 12
Curitiba 12
Zhengzhou 12
Boston 11
Contagem 11
Fuzhou 11
Poplar 11
Betim 10
Biên Hòa 10
Francofonte 10
Helsinki 10
Manchester 10
Osasco 10
Quito 10
Ribeirão Preto 10
Washington 10
Bogotá 9
Guayaquil 9
Norwalk 9
Nuremberg 9
Totale 14.502
Nome #
1,3-diidro-benzimidazoloni analoghi: progettazione, sintesi e SAR di nuovi inibitori non-nucleosidici dell'RT 4.566
1-Aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide derivatives: synthesis and biological evaluation 231
Chemical exploration of 4-(4-fluorobenzyl)piperidine fragment for the development of new tyrosinase inhibitors 201
AMPA receptor antagonists: Synthesis and pharmacological evaluation 169
Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases 166
4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. 152
Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments 152
A New 3D Pharmacophore Model for HIV-1 Integrase Strand Transfer Inhibitors. 149
Design and optimization of isoquinoline-sulfonamides as potent and selective inhibitors of human carbonic anhydrase VII 149
3D Pharmacophore model and synthesys of NMDA receptor subunit NR2B antagonists 144
A new potential approach to block HIV-1 replication via protein–protein interaction and strand-transfer inhibition 143
Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety 142
Carbonic anhydrase inhibitors: Design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms 141
Identification of Potent and Selective Human Carbonic Anhydrase VII (hCA VII) Inhibitors 140
A New 3D Pharmacophore Model for HIV-1 Integrase Strand Transfer Inhibitors 139
A refined pharmacophore model and optimization of 1H-benzylindole HIV-1 integrase inhibitors 138
A structure-based approach to ligand discovery for inhibition of HIV-1 IN-LEDGF/p75 interaction: a new target for anti-AIDS therapy 136
InVivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents 136
Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis 133
DISCOVERY OF NEW INDOLE DERIVATES AS NEUROPROTECTIVE AGENTS 131
Microwave-assisted synthesis of benzimidazole and thiazolidinone derivatives as HIV-1 RT inhibitors 130
Graphene Quantum Dots Based Systems As HIV Inhibitors 130
Antiretroviral strategy using multi-target agents 129
Identification of isoquinoline-sulfonamides as potent and selective carbonic anhydrase inhibitors 127
Combined strategies for the discovery of ionotropic glutamate receptor antagonists 126
3D pharmacophore model and the synthesis of NMDA receptor subunit NR2B antagonists 126
Binding mode investigation and SAR studies of HIV-1 integrase inhibitors 125
Modificazioni strutturali del gruppo dichetoacido (DKA) di potenti inibitori dell'Integrasi dell'HIV-1 124
Discovery of potent and selective inhibitors of druggable carbonic anhydrase isoforms 123
Searching for indole derivatives as potential mushroom tyrosinase inhibitors 122
Synthesis and anti-HIV activity of carboxylated and drug-conjugated multi-walled carbon nanotubes 121
Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. 121
HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation 121
Combined ligand-based and target-based approach to design NR2B/NMDA receptor antagonists 120
PROGETTAZIONE E SINTESI DI NUOVI DKA ANALOGHI COME POTENZIALI INIBITORI DELL’INTEGRASI DELL’HIV-1 120
Synthesis and structure-active relationship of 1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline anticonvulsants 120
Nuovi ligandi del recettore NR2B/NMDA a struttura indolica 119
Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as Potent Carbonic Anhydrase Inhibitors: Synthesis, Biological Evaluation, and Enzyme−Ligand X-ray Studies 119
Analysis of Italian regulations on pathways of care for patients in a vegetative or minimally conscious state 119
Nuovi Antagonisti Non-Competitivi Del Recettore NMDA/NR2b: Design e Sintesi” 117
Small Molecules Targeting Protein–Protein Interactions: A Promising Anti-HIV Strategy 117
Inhibitors of the Interactions between HIV-1 IN and the Cofactor LEDGF/p75 117
From 3D-pharmacophore models to synthetic route towards anti-HIV agents 116
From NMDA receptor antagonists to discovery of selective σ2 receptor ligands 115
Synthesis of new pyridazine derivatives as potential anti-HIV-1 agents 113
Probing the molecular interactions between the human Carbonic Anhydrases (hCAs) and a novel class of benzenesulfonamides 113
Discovery and optimization of isoquinoline-derived inhibitors of human Carbonic Anhydrases (hCAs) 113
Design e Sintesi di composti a struttura 3-Indol-Gliossilamidica come potenziali inibitori dell'integrasi dell'HIV-1. 112
Synthesis and SAR of new 1,3-dihydro-benzimidazolone analogues as non-nucleoside reverse transcriptase inhibitors (NNRTIs) 112
Derivati benzimidazolonici ed analoghi come potenti inibitori non-nucleosidici dell'RT dell'HIV-1 110
Serendipitous discovery of indole derivatives as potent tyrosinase inhibitors 110
Computational and synthetic approaches for developing Lavendustin B derivatives as allosteric inhibitors of HIV-1 integrase 110
Sintesi e SAR di nuovi inibitori dell'acetilcolinesterasi come potenziali agenti anti-Alzheimer 109
PROGETTAZIONE E SINTESI DI NUOVI DERIVATI ISOCHINOLINICI COME AGENTI ANTICONVULSIVANTI MULTITARGET 108
Computational Studies to Discover a New NR2B/NMDA Receptor Antagonist and Evaluation of Pharmacological Profile 108
Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors”. Antiviral Research 108
New indole derivatives as promising ligands for ifenprodil site of NR2B/NMDA receptors 108
PROGETTAZIONE E SINTESI DI NUOVI DKA ANALOGHI COME POTENZIALI INIBITORI DELL'INTEGRASI DELL'HIV-1 107
Insight into the INSTIs binding mode: molecular modeling investigation and SAR studies 107
Discovery of potent HIV-1 integrase strand transfer inhibitors: design and synthetic strategies 105
Synthesis, biological evaluation and docking studies of NR2B/NMDA receptor antagonists 105
NOVEL N1-ARYL-2- ARYLTHIOACETAMIDOBENZIMIDAZOLES WERE EFFECTIVE AGAINST HERPES SIMPLEX VIRUS 1 (HSV-1) REPLICATION IN VITRO 105
Discovery of HIV-1 Integrase and cellular cofactor LEDGF/p75 interaction inhibitors 104
Antiretroviral strategy: design and synthesis of HIV-1 IN-LEDGF/p75 interaction inhibitors 104
Synthesis, Structure-Activity Relationship Studies, and X-ray Crystallographic Analysis of Arylsulfonamides as Potent Carbonic Anhydrase Inhibitors. 104
Synthesis and biological characterization of novel potent arylsulfonamides as human carbonic anhydrase inhibitors (hCAIs) targeting central nervous system 104
Searching for NR2B/NMDA Receptor Antagonists As Neuroprotective Agents 103
Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides. 103
Simulated human digestion of N1-aryl-2-arylthioacetamidobenzimidazoles and their activity against Herpes-simplex virus 1 in vitro 103
Novel targets for HIV therapy: small molecules blocking IN-LEDGF/p75 interaction 102
Progettazione, Sintesi e SAR di analoghi 1,3-diidro-benzimidazoloni come nuovi agenti anti-HIV 102
Combined strategies for the discovery of ionotropic glutamate receptor antagonists 101
HIV-1 integrase strand-transfer inhibitors: design and synthetic strategies in the process of a lead optimization 100
Design, Synthesis and Biostructural Characterization of Carbonic Anhydrase Inhibitors 100
Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists 100
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series 99
Computational and synthetic approaches for the discovery of HIV-1 integrase inhibitors 99
Computational studies and synthetic approaches for the identification of new protein-protein interaction inhibitors (PPI) 99
Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides 99
Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors 99
Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors 98
INTEGRASE STRAND TRANSFER INHIBITORS (INSTIs): SYNTHESIS AND ANTIVIRAL EFFETCS OF CHLORO-FLUORO SUBSTITUTIONS 98
Design, synthesis and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents 97
Identification of potent carbonic anhydrase inhibitors: synthesis, biological evaluation and enzyme-ligand x-ray studies 97
Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors 97
Computational and synthetic approaches for the discovery of HIV-1 integrase inhibitors 96
HIV-1 integrase strand transfer inhibitors (INSTIs): design, synthesis and biological activity 96
New potent and selective carbonic anhydrase inhibitors: synthesis, biological evaluation and X-ray studies 96
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: Synthesis, biological evaluation, and molecular modeling studies 96
Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains 96
Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors. 95
N-Substituted Isoquinoline Derivatives as Potential AChE Inhibitors 93
Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors 92
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action 91
Identification of 3-substituted-1H-indoles as ligands of GluN2B containing N-methyl-D-aspartate receptors 91
Progettazione razionale e "green" sintesi di nuovi inibitori dell'integrasi dell'HIV-1 90
MOLECULAR MODELING STUDIES AND SYNTHESIS FOR THE DISCOVERY OF HIV-1 IN-LEDGF/P75 INTERACTION INHIBITORS 90
HIV-1-IN Strand-Transfer Inhibitors: phenyl ring exploration and synthesis of 1H-benzylindole derivative through fluorine substitutions 89
ISOQUINOLINE-SULFONAMIDES AS A CLASS OF POTENT AND SELECTIVE CARBONIC ANHYDRASE INHIBITORS 88
Rational design, synthesis and evaluation of coumarin derivatives as protein-protein interaction inhibitors 88
Totale 16.044
Categoria #
all - tutte 62.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.027


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021739 0 0 0 0 0 123 17 142 38 142 85 192
2021/20221.060 10 161 25 48 38 11 81 39 28 11 258 350
2022/20232.901 242 254 143 218 212 297 54 148 1.232 8 74 19
2023/2024682 57 102 50 134 56 124 7 16 1 56 14 65
2024/20253.163 59 46 59 181 109 123 53 728 804 185 277 539
2025/20269.725 363 1.970 3.725 886 780 2.001 0 0 0 0 0 0
Totale 21.048